Weight-Loss Pills vs Injections: Why GP-Led Assessment Still Matters

A new Wegovy tablet has been approved in the UK for weight loss and weight management, creating fresh interest in prescription weight-loss treatment.

It is the UK’s first GLP-1 tablet licensed specifically for weight management. It contains semaglutide, the same active ingredient used in the weekly Wegovy injection, but it is taken once every day.

For people who dislike needles, a tablet may initially sound like the easier option. In practice, however, the way it is taken matters.

The Wegovy tablet must be taken after fasting for at least eight hours. After swallowing it, patients must wait at least 30 minutes before eating, drinking or taking another oral medicine. Taking it incorrectly can reduce how much semaglutide the body absorbs.

This means the choice is not simply between a “simple pill” and a more complicated injection. One option involves a weekly injection, while the other requires a consistent daily routine.

Prescription weight-loss treatment is still medical treatment, regardless of how it is taken. It is not suitable for everyone and should not be treated like a casual wellness product.

Safe care starts with proper clinical assessment. That includes checking eligibility, reviewing medical history and other medicines, explaining how treatment must be taken, discussing possible side effects and providing ongoing clinical review.

The MHRA approved the once-daily tablet on 11 June 2026. It remains a prescription-only medicine and is not currently available through the NHS while decisions about NHS use go through the established NICE assessment process.

Weight is not just a cosmetic issue.

In England, 30% of adults were living with obesity in 2024, and 66% were either overweight or living with obesity.

Obesity can be linked with higher risk of conditions such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea, joint problems and cardiovascular disease.

This is one reason medical weight-loss treatment is getting more attention. But more attention also brings more confusion.

Patients may wonder:

• Am I eligible?
• Is a tablet safer than an injection?
• Can I switch from injections to tablets?
• What are the side effects?
• Can I buy treatment online safely?
• Do I need blood tests?
• Do I still need to see a doctor?

The answer depends on the individual. That is why GP-led assessment matters.

Eligibility is usually based on BMI, weight-related health conditions, medical history and clinical assessment.

The MHRA approval for the Wegovy tablet applies to adults with:

• a BMI of 30 or above
• or a BMI of 27 to 30 with at least one weight-related health condition

Weight-related conditions may include:

• high blood pressure
• high cholesterol or dyslipidaemia
• pre-diabetes
• type 2 diabetes
• obstructive sleep apnoea
• polycystic ovary syndrome
• fatty liver disease
• osteoarthritis
• reflux or other weight-related health concerns

These criteria are not a guarantee of treatment. They are a starting point for assessment.

A GP still needs to consider your health as a whole, including your current medication, symptoms, previous weight-loss attempts, family history, mental health, eating-disorder history, pregnancy plans and any long-term conditions.

Some people may meet the BMI criteria but still not be suitable for medication.

BMI can be useful, but it does not tell the whole story.

Two people with the same BMI may have very different health risks. One person may have high blood pressure, raised cholesterol or pre-diabetes. Another may have a history of pancreatitis, complex medication, pregnancy plans, stomach problems or mental health concerns that affect whether treatment is suitable.

A GP assessment can help look at the wider picture, including:

• weight and BMI
• blood pressure
• cholesterol
• blood sugar risk
• liver and kidney health
• current medication
• previous side effects
• appetite, eating patterns and lifestyle
• wider medical history

This helps make treatment decisions safer and more personalised.

Prescription weight-loss medication is not right for everyone.

Treatment may not be suitable, or may need extra caution, if you are pregnant, breastfeeding, planning pregnancy, under 18, taking certain diabetes medicines, already using another weight-loss medicine, or have certain stomach, pancreas, kidney, eye, thyroid, mental health or eating-disorder risks.

This is not a full list. The details matter, and suitability can depend on the specific medicine being considered.

DocTap's treatment information page explains current eligibility criteria, cautions and situations where medication cannot be prescribed.

A tablet can sound less medical than an injection, but prescription weight-loss tablets can still cause side effects.

Common side effects of GLP-1 treatment can include nausea, reflux, constipation, diarrhoea or vomiting. For some people, these symptoms are mild and settle. For others, they may be harder to manage or may need medical advice.

Most gastrointestinal side effects are mild or moderate, but persistent vomiting or diarrhoea can sometimes lead to severe dehydration.

The MHRA strengthened its warning about acute pancreatitis in January 2026. Anyone taking a GLP-1 medicine who develops severe and persistent abdominal pain—particularly pain that spreads to the back and may be accompanied by nausea or vomiting—should seek urgent medical help.

Semaglutide has also been associated with a very rare eye condition called non-arteritic anterior ischaemic optic neuropathy, or NAION. The MHRA estimates that it may affect up to one in 10,000 people taking semaglutide. Sudden loss of vision or rapidly worsening eyesight requires urgent assessment through eye casualty or A&E.

Patients should also tell their healthcare team that they use a GLP-1 medicine before surgery or a procedure involving general anaesthesia or deep sedation. These medicines slow stomach emptying and may affect the risk assessment and preparation for the procedure. Patients should not stop treatment before surgery unless advised to do so by their clinician.

You should speak to a clinician if side effects are persistent, severe, worsening, or if you are struggling to eat, drink or stay hydrated.

You should also speak to a GP before starting treatment if you have existing medical conditions, take regular medication, or have had side effects from weight-loss medicines before.

The Wegovy tablet is taken once a day, rather than once a week like the injection.

To help the body absorb the medicine properly, the official instructions state that it should be:

• taken on an empty stomach after fasting for at least eight hours
• swallowed whole with a small amount of plain water
• taken without food, coffee, tea, juice or other drinks
• followed by a wait of at least 30 minutes before eating or drinking
• followed by the same 30-minute wait before taking another oral medicine

The tablet should not be split, crushed or chewed.

Waiting less than 30 minutes before eating, drinking or taking another medicine reduces the absorption of semaglutide. This could make treatment less effective.

For many people, the most practical approach may be to take it immediately after waking, wait for at least 30 minutes, and then have breakfast and take any other morning medication. However, the correct routine should be discussed with the prescriber, particularly if someone takes important medicines at a set time each morning.

The fasting requirement is a significant difference between the Wegovy tablet and injectable weight-loss medicines.

No. People starting the tablet would not normally begin with the full 25mg dose.

The MHRA-approved schedule starts at:

• 1.5mg once daily
• increasing to 4mg once daily
• then 9mg once daily
• followed by the 25mg maintenance dose

Patients should generally remain at each dose for at least one month before moving to the next level.

Gradually increasing the dose gives the body time to adjust and may help make gastrointestinal side effects more manageable. Dose increases should follow the prescriber’s instructions rather than being accelerated because someone wants faster results.

That depends on the patient.

The tablet may be preferable for someone who:

• is uncomfortable with needles
• does not feel confident using an injection pen
• prefers taking conventional oral medication
• travels frequently and finds injectable treatment inconvenient

However, the tablet also requires:

• daily dosing
• an overnight fast of at least eight hours
• a specific morning routine
• a wait before breakfast, drinks and other oral medication
• consistent adherence every day

By comparison, Wegovy and Mounjaro injections are taken once weekly and do not have the same daily fasting routine.

Someone who dislikes injections may find the tablet much easier. Someone who already takes several morning medicines, works irregular shifts or struggles with daily medication may find a weekly injection more practical.

The best option is therefore not necessarily the one that sounds easiest. It is the treatment that is clinically suitable and that the patient can use safely and consistently.

Wegovy and Mounjaro are prescription-only medicines used in medical weight-loss treatment where clinically appropriate.

DocTap’s treatment information page explains the current injectable treatment options, including Wegovy and Mounjaro, as well as eligibility, pricing, prescribing, repeat requests and delivery.

The new tablet is not a tablet version of Mounjaro. It contains semaglutide, making it an alternative formulation of Wegovy.

It should also not be confused with Rybelsus. Rybelsus contains semaglutide in tablet form but is licensed for type 2 diabetes, not weight management. Ozempic is also licensed for diabetes rather than weight loss.

The brand, formulation, strength and licensed purpose all matter. Patients should not substitute one semaglutide product for another without medical advice.

The approval of a tablet does not mean everyone should switch, or that tablets are automatically better than injections.

The right option depends on your health, suitability, preferences, side-effect risk, current medication and GP assessment.

Some people already using Wegovy injections may be interested in moving to the tablet.

The MHRA states that patients being treated privately with the 2.4mg once-weekly semaglutide injection can be transitioned to the 25mg once-daily tablet. However, this should only happen under the direction of a prescriber.

It does not mean that everyone using an injection should automatically switch.

A doctor still needs to consider:

• which medicine the patient is currently taking
• the current dose
• how long they have used it
• weight-loss progress
• side effects
• any treatment interruptions
• other health conditions and medicines
• whether the daily fasting routine is practical

The specific transition described by the MHRA applies to patients established on the 2.4mg Wegovy injection. It should not be interpreted as a direct switching rule for Mounjaro, lower doses of Wegovy or other weight-loss treatments.

Do not combine tablets and injections, overlap doses or calculate a switch yourself. Speak to your existing prescriber before making any change.

Interest in weight-loss medication has also led to a rise in unregulated sellers, fake products and social-media offers.

This is risky.

Prescription weight-loss medicines should only be supplied after proper clinical assessment by a regulated provider.

You should not buy prescription weight-loss medication from social media sellers, beauty salons, informal contacts, or any website that does not include a proper consultation with a healthcare professional.

Fake or incorrectly supplied medicines may contain the wrong ingredient, the wrong dose, unsafe ingredients, or no active medicine at all.

If you are considering medical weight-loss treatment, use a regulated healthcare provider and make sure you have access to follow-up if anything goes wrong.

Medical weight loss should not be just a form and a prescription.

A GP-led approach looks at the whole person, not just the number on the scales.

At DocTap, your GP can review your health, check your weight and suitability, discuss your medical history, and arrange blood tests or checks where needed. GP-led medical weight loss

If treatment is suitable and clinically safe, your GP can discuss appropriate options and next steps. If medication is not suitable, you still receive medical advice and a clear plan.

Booking a consultation does not guarantee a prescription. Medication is only issued where clinically appropriate.

Not everyone needs the same checks before starting weight-loss treatment, but some people benefit from knowing their baseline health numbers.

Depending on your situation, a GP may discuss:

• blood pressure
• weight and BMI
• cholesterol
• HbA1c, which reflects average blood sugar over the last few months
• liver function
• kidney function
• thyroid function
• current medication
• weight-related health conditions

These checks can help guide treatment decisions and make follow-up more meaningful.

If you are starting treatment because of wider health concerns, it can be useful to understand where you are starting from, not just whether medication is available.

Weight-loss treatment should not be "set and forget".

Your response to treatment, side effects, weight change, appetite, hydration, mood, medication and health changes may all affect what happens next.

A GP may need to review whether to continue, adjust, pause or stop treatment.

At DocTap, repeat prescriptions are reviewed by a GP. Patients provide updates through their DocTap account, including current weight, side effects and any significant health changes.

This review step helps make sure treatment remains appropriate and safe over time.

It is worth speaking to a GP if you are considering medical weight-loss treatment and:

• you are unsure whether you are eligible
• you have a medical condition
• you take regular medication
• you have had side effects from weight-loss treatment before
• you are already using injections and want to discuss options
• you have diabetes, high blood pressure or high cholesterol
• you have a history of pancreatitis
• you are pregnant, breastfeeding or planning pregnancy
• you have a current or previous eating disorder
• you are buying or considering treatment from an online provider and feel unsure

A GP can help you understand what is appropriate, what is not suitable, and what to avoid.

DocTap offers GP-led medical weight-loss appointments in London.

Your appointment can include:

• assessment of your eligibility and suitability
• review of your medical history and current medication
• weight, BMI and health-risk checks
• discussion of the benefits and limitations of different treatments
• blood tests where clinically appropriate
• advice about side effects and what symptoms require help
• ongoing GP review if treatment is prescribed

DocTap currently offers injectable weight-loss treatment, including Wegovy and Mounjaro, where it is clinically appropriate.

The Wegovy tablet is not currently available through DocTap. We are preparing to add it to our GP-led weight-loss service and will update our treatment information when it becomes available.

When introduced, it will not be offered as an automatic or easier alternative to injections. Patients will still need an initial clinical assessment, eligibility checks, prescribing advice and ongoing review.

For some people, avoiding injections will be an important advantage. For others, taking a tablet every day after an eight-hour fast—and waiting before breakfast, coffee or other medication—may be less convenient than a weekly injection.

Treatment is only prescribed when it is clinically suitable and safe. Booking a consultation does not guarantee a prescription.

Medical weight loss should be safe, supported and realistic. The right treatment depends not only on which medicine may support weight loss, but also on medical suitability, potential risks and whether the patient can follow the treatment routine consistently.

If you are considering medical-weight-loss support, start with a GP-led consultation.